Malignant epithelioid mesothelioma
disease diseaseOn this page
Also known as epithelial mesotheliomaepithelioid mesotheliomaepithelioid mesothelioma, malignantepithelioid mesothelioma, malignant (morphologic abnormality)malignant epithelial mesothelioma
Summary
Malignant epithelioid mesothelioma (MONDO:0005599) is a disease and 14 clinical trials. Top therapeutic interventions include belinostat, erlotinib hydrochloride, and gefitinib. A subtype of malignant mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | malignant epithelioid mesothelioma |
| Mondo ID | MONDO:0005599 |
| EFO | EFO:0006452 |
| DOID | DOID:4489 |
| NCIT | C7985 |
| UMLS | C0862312 |
| MedGen | 163578 |
| GARD | 0024208 |
| Is cancer (heuristic) | no |
Also known as: epithelial mesothelioma · epithelioid mesothelioma · epithelioid mesothelioma, malignant · epithelioid mesothelioma, malignant (morphologic abnormality) · malignant epithelial mesothelioma
Disease family
This is a subtype of malignant mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mesothelioma › malignant epithelioid mesothelioma
Related subtypes (10): ovarian malignant mesothelioma, malignant pericardial mesothelioma, malignant pleural mesothelioma, malignant peritoneal mesothelioma, malignant biphasic mesothelioma, sarcomatoid mesothelioma, localized pleural mesothelioma, diffused pleural mesothelioma, pleural mesothelioma in situ, mesothelioma of the tunica vaginalis
Subtypes (1): pleural epithelioid mesothelioma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01064648 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma |
| NCT00025207 | PHASE2 | COMPLETED | Gefitinib in Treating Patients With Malignant Mesothelioma |
| NCT00027703 | PHASE2 | COMPLETED | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma |
| NCT00039182 | PHASE2 | COMPLETED | Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung |
| NCT00107432 | PHASE2 | COMPLETED | Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. |
| NCT00243074 | PHASE2 | COMPLETED | S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery |
| NCT00309946 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery |
| NCT00365053 | PHASE2 | COMPLETED | PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery |
| NCT01105390 | PHASE2 | WITHDRAWN | AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma |
| NCT01861301 | PHASE2 | TERMINATED | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma |
| NCT02399371 | PHASE2 | COMPLETED | Pembrolizumab in Treating Patients With Malignant Mesothelioma |
| NCT03228537 | PHASE1 | ACTIVE_NOT_RECRUITING | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma |
| NCT00585845 | PHASE1 | TERMINATED | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment |
| NCT04034238 | PHASE1 | COMPLETED | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BELINOSTAT | 4 | 1 |
| ERLOTINIB HYDROCHLORIDE | 4 | 1 |
| GEFITINIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 3 |
| RILOTUMUMAB | 3 | 1 |
| TIVANTINIB | 3 | 1 |
| LMB-100 | 2 | 1 |
| CHEMBL4475379 | 0 | 1 |
| CHEMBL4785734 | 0 | 1 |
Related Atlas pages
- Drugs: Belinostat, Erlotinib, Gefitinib, Sorafenib, Cediranib, Rilotumumab, Tivantinib